Compare FSLY & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | MDXG |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2019 | 2007 |
| Metric | FSLY | MDXG |
|---|---|---|
| Price | $20.25 | $4.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | ★ 18.6M | 748.2K |
| Earning Date | 05-13-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.19 | 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $624,018,000.00 | $418,630,000.00 |
| Revenue This Year | $15.51 | N/A |
| Revenue Next Year | $11.32 | $13.14 |
| P/E Ratio | ★ N/A | $14.08 |
| Revenue Growth | 14.78 | ★ 19.99 |
| 52 Week Low | $4.65 | $4.48 |
| 52 Week High | $21.75 | $8.20 |
| Indicator | FSLY | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 70.22 | 24.89 |
| Support Level | $7.43 | N/A |
| Resistance Level | $20.27 | $5.38 |
| Average True Range (ATR) | 1.82 | 0.19 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 70.22 | 2.55 |
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.